Marijuana Stocks of the Week: BeLeave, Cannabics (CNBX) with Jeffrey Friedland / cannabis weed pot 2017 canada hemp investing robinhood to buy now invest in canadian medical Canopy Growth Mentor Capital TWMJF WEED david moadel
welcome to looking at the markets with David Modell today my special guest is
mr. Jeffrey Friedland mr. Freedland is a world-renowned expert in the marijuana
stocks and marijuana company's niche as well as a published author one of his
books that I like so much in that I think is a classic is called marijuana
the world's most misunderstood plant so you're going to want to go into the
description in this YouTube video and there's a link to get that book on
Amazon and also check out www.hsn.com
one or a Canadian one okay so we'll do today we'll do a Canadian one first and
then we'll go to we'll go stateside to the United States but you know we're
also looking worldwide and we get our ideas from you by the way you the viewer
you you've been telling us which countries I'm sorry which companies you
are interested in having mr. friedlin discuss with me every week so please go
ahead and put those suggestions in the comments section in the YouTube video
and also email me your suggestions at David Modell at gmail.com alright so the
first company we're going to discuss today is called be leave ink and the
ticker symbol for that is B e in Canada or BL e VF ble VF that's in the United
States if you want trade or invest in that one later on in this video we're
going to discuss cannabis Pharmaceuticals Inc and
ticker symbol for that is CNB x and that's American
alright so Jeff let's talk about believe Inc first the Canadian company but as I
said it's these shares trade both in Canada and the United States so what can
you tell us first of all about the stock price or the trading of believe Inc
right you know the stock closed yesterday David in a dollar twenty two
US dollars these are US dollars obviously the price in Canada is a
little bit different the 52-week range which you and I are always sensitive to
is a low of ninety-five cents and a higher of adult high of a dollar fifty
one so it's trading nowhere near David its 52-week high it's in between you
know a lot of our viewers don't want to buy something if it's at the 52-week
high the market cap is 39 million again US dollars that's not a lot for a
Canadian licensed producer gotcha alright and what can you tell us about
the business of believe Inc okay a belief is a what's called a license
producer in Canada and what that means David is they're licensed by Health
Canada which is the national healthcare system in Canada as a producer of
cannabis marijuana and in Canada it's really right now about all the licensed
producers who are licensed on the medical side David they're all
anticipating next year's adult use regime in Canada which is to kick in on
Canada Day July 1 2018 so a large to a large extent all the companies we talked
about that are licensed producers they're on the medical side they really
view the real opportunities up there on the adult use or recreational side sure
and what can you tell us Jeff about the status of the company's business
operations right in late May they were approved by Health Canada as a producer
they were able to produce but they have not gotten the approval yet to sell and
that's sort of a two-step process in Canada first you
and then you go in and you do independent testing to see if there's no
pesticides etc and then you you know seek approval to be able to sell so
right now they're not able to sell and you know may 19th as a licensed producer
there in Ontario it's crowded space they're late to the game definitely know
first to market advantage David hmm okay that's something to think about now
there might have been recent developments in regard to believes
cannabis cultivation operations can you tell us about that yeah in late
September almost October they brought in their first to grow their there two
batches of grows so they've got two batches to grow cycles in the vault
being dried waiting for testing and they announced then that they would go ahead
David and then as soon as they had those test results apply for a license from
Health Canada to be able to sell I haven't even though that was a month
and a half ago I haven't seen anything that they've gone into a request that
license to sell yet they haven't announced that they may have gone in
already a requested and just haven't announced it mm-hmm okay and this might
be a red flag I heard there was a recent a change in their management at believe
is that true yeah when you have an early stage company it's a little bit of a
warning signal I think for investors and all our viewers David if at an early
point in time you changed management and they announced the new CEO Andrew when
neck w Nek and dr. Roger Ferreira who was CEO moved in to the role of chief
science officer so when you see something like this you always try to
think what happened why my guess is that change was mandated by the Board of
Directors or their investment bankers or outside advisers and they had a guy who
obviously was a founder heading the company he probably didn't have
the business sensibility or didn't want to be in that role moved him into the
science role presumably brought somebody in who's better at management I wish we
had more information more insight on that doesn't give someone a warm and
fuzzy feeling without some backup as to why hmm sounds like there might be some
unanswered questions there so bottom line what are your conclusions about
believe Inc buy sell hold all right so what we want is the bottom line for
believe Inc what do you think Jeff is this a buy hold or sell right the market
cap doesn't really bother me for a Canadian licensed producer my concern is
David there in Ontario it's crowded space up there there's a lot of licensed
producers up there they're very very very late to the game definitely no
first mover advantage they have no ability to sell their product right now
they're cannabis Iowa we have no idea as to whether they've applied to Health
Canada what the test results were yet to be able to have the ability to sell so
my thing there the key thing in Canada under the health regime up there right
now is to have a market to sell to on the medical side so you know the
question is who are they going to sell to if and when they're given approval to
sell because you know some companies some licensed producers in Canada are
selling nursing homes either have unique distribution channels I am Not sure
what's left so I'm not sure what they end up doing but part of Canada is all
about positioning for adult use of recreational next July that's to a large
extent probably what believe is about as well so my suggestion to our viewers is
watch this one see if and when they get approval to sell see what their
distribution channels are let's see if they can actually sell some medical
cannabis and let's see if they're able to function under the new if they're
able to get a license for adult use if our viewers if one of you our viewers
were looking to put together a portfolio of all
we traded Canadian license producers I'd say buy some otherwise sit on the
sidelines watch this one and I think David we should you and I should make a
note of this one that once they get approval assuming they do to sell let's
take a look at what their distribution direction is got it all right so Jeff
let's get things underway on the American side of things with cannabis
Pharmaceuticals Inc CNB X first of all what can you tell us about how those
shares are trading right it closed yesterday David at 82 cents obviously
trades us we always look at 52 week high again just like we did with the last
company so 52 week law was 35 hi seven dollars and sixty cents which
is like almost ten times where it's trading now so if someone were to buy
this it's definitely way way way off the 52 week high on the market cap is 97
million my personal conclusion I mean I know you and I discussed this company
you know yesterday a bit I was a bit more bullish yesterday than today I
think it's a very aggressive high valuation based on what they have got it
all right and let's get to basics here what is the business of cannabis
pharmaceuticals yeah that's a really good question and I you know to drill
down on this company let's keep in mind what pharmaceuticals are really at the
end of the day the company's name is cannabis pharmaceuticals the first thing
comes to mind David is we go to Walgreens Rite Aid or CBS and we get a
real pharmaceutical well this company is really not about pharmaceuticals it's
really about personalized diagnostic tools what does that mean in English
here in the United States we have state licensed marijuana and there's really no
real science you know if you walk into a budtender in a store most of whom retail
store dispensary they're passionate about what they do and you say I've got
you know arthritis in my knee or I've got pain or sleep
they make recommend so what Tana Bix is trying to do is to
provide personalized diagnostic tools so that the patient can for lack of better
word self-prescribed and be able to figure out what strain what combination
of cannabinoids what to ask their local budtender for so this is not about
pharmaceuticals despite that being in their name
it's not about drug development you know I think it's interesting a couple things
so it's about diagnostic tools personalized medicine patients
controlling their own you know what they're going to use with herbal
cannabis medicine that they would get from state licensed businesses there are
Dee's in Israel that's obviously a big deal you know we've talked about on
other companies the role of Israel in the cannabis space they're focusing to a
large extent on diagnostic tools for cancer patients again you know if
someone has cancer some science is better than no science and being able to
have an ability to try to determine what potentially could work best as far as a
strain or a mix of cannabinoids could be beneficial for many many cancer patients
David they are working on I mean they're to some extent on pharmaceuticals they
have some capsules cannabis capsules as a treatment for advanced cancer patients
but I don't know what they're really doing in Israel
that's definitely does not appear to be on a US Food and Drug Administration FDA
tract it appears that they might be trying to
plug that into their diagnostic tools but this company is really about
diagnostic tools it's not about coming up with a cure for cancer in my opinion
and it doesn't appear at all to be about pharmaceuticals that we would be able to
get a real prescription from a doctor go to Walgreens Rite Aid get a prescription
have it paid by healthcare so I would see this company really as a diagnostic
company all right now let's talk about the patents for
cannabis pharmaceuticals what their patent strategy as far as you can
tell well they've filed a lot of patents on this personalized medicine direction
so not pharmaceutical again and that's one of the concern with their capsules
you know they're obviously indicated they're doing some trials I put some
trials in quotes in Israel I don't know if they have any potential patent
protection if they do develop a herbal medicine that maybe they bring to the
California or Colorado or Illinois markets but most of the patents that
I've been able to find on this or all about personal medicine etc so that's
what they're really doing you know what it potentially is interesting yeah and
speaking of patents I remember this summer cannabis filed a patent
application in regard to a collaboration or agreement with a German company
what's that all about yeah into this collaboration agreement
with C sorry s IM f which is a world leader I'm putting that
in quotes their words not mine in cancer diagnostics and liquid biopsies so again
I think what they're trying to do there is to for cancer patients plug in their
diagnostic tools into what's happening in Germany presumably patients will be
able to send blood samples in and then get back some data to be able to use
presumably with state license regimes or equivalent in other countries to help
presumably their physicians or for themselves to be able to self diagnose
so it could be interesting but very very very early stage mm all right so again
we love the bottom line here at looking on the markets so what do you think
about cannabis pharmaceuticals viewers own the stock already sure they hold it
and if they don't should they buy it well this is way off from a 52-week I so
unless on our viewers have a huge you know a profit on other stocks that they
need a tax loss on I would hang in there because it's off it's 10% of
52-week high but if if if viewers believe and David the whole
pharmaceutical side as opposed to the adult use of recreational if they're
trying to put together a portfolio pharmaceutical related companies I don't
think it's bad to pick up a few shares on this but I think the valuation is
still high for what they're doing it's unclear how they would monetize
these personalization tools how they get the cash register to ring there's lots
of questions on this cancer trial in Israel as far as patents no disclosure
what that pathway is in Israel what that science if they're successful does for
them so I mean I'm not buying any I mean you and I don't own any stocks when we
talked about on this show but I'm sitting on the sidelines I think it's
very very early early stage if it was a third or a fourth the words now trading
based on market cap it could be more interesting but I I think this is a
long-term strategy for this company but having said that the 52-week range David
is obviously been huge and that means to those our viewers who are traders who
you know sit watching their screen there could be a tremendous opportunity with
this company because of fluctuations to sort as they say buy low sell high and
that could happen quite a few times over a month so that could be interesting
that's not investing that's trading and we will continue to monitor believe and
cannabis pharmaceuticals we may revisit them at a later time and as viewers you
can let us know here at looking at the markets what you want to see maybe you
want us to revisit a company we haven't spoken about in a while that's okay or
maybe you've got some new suggestions for us my email address once again David
Modell at gmail.com and also leave you know give a like a comment you know and
any suggestions you have put them in the youtube video comments section also
don't forget to check out
plenty of resources over there for you to look at also get a copy if you
haven't done it already please get a copy on Amazon of mr. Freed's Lin's book
marijuana the world's most misunderstood plants the link will be the amazon link
will be in the description of this video or just go on Amazon put it in the
little box there that says search and you'll find it no doubt alright so we're
gonna keep coming back every week with two different companies in the marijuana
space and we'll discuss them and help you to make decisions on your own so
thanks a lot once again Jeffrey Friedman for coming on - looking at the markets
see you next week David thank you for watching please like comment and
subscribe and I'll see you next time
No comments:
Post a Comment